{"result": "(\"entity\"<|>HOSPITAL UNIVERSITARIO CRUCES<|>ORGANIZATION<|>Hospital Universitario Cruces is a medical facility where Fco. Javier Santamaría Sandi works as the head of the Endocrinology and Nutrition section since 2007.)\n##\n(\"entity\"<|>FCO. JAVIER SANTAMARÍA SANDI<|>PERSON<|>Fco. Javier Santamaría Sandi is a specialist in Endocrinology and Nutrition, currently the head of the Endocrinology and Nutrition section at Hospital Universitario Cruces and an associate professor at the University of the Basque Country.)\n##\n(\"entity\"<|>UNIVERSIDAD DEL PAÍS VASCO<|>ORGANIZATION<|>The University of the Basque Country is an educational institution where Fco. Javier Santamaría Sandi serves as an associate professor in the Department of Medicine.)\n##\n(\"entity\"<|>SEDYNE<|>ORGANIZATION<|>The Society of Endocrinology, Diabetes and Nutrition of Euskadi (SEDyNE) is a professional organization that Fco. Javier Santamaría Sandi presided over from March 2011 to March 2016.)\n##\n(\"entity\"<|>CÁNCER DE TIROIDES<|>EVENT<|>The Thyroid Cancer Working Group is a committee within the Society of Endocrinology and Nutrition in Spain that Fco. Javier Santamaría Sandi served as secretary from 2012 to 2016.)\n##\n(\"relationship\"<|>FCO. JAVIER SANTAMARÍA SANDI<|>HOSPITAL UNIVERSITARIO CRUCES<|>Fco. Javier Santamaría Sandi is the head of the Endocrinology and Nutrition section at Hospital Universitario Cruces<|>9)\n##\n(\"relationship\"<|>FCO. JAVIER SANTAMARÍA SANDI<|>UNIVERSIDAD DEL PAÍS VASCO<|>Fco. Javier Santamaría Sandi is an associate professor at the University of the Basque Country<|>8)\n##\n(\"relationship\"<|>FCO. JAVIER SANTAMARÍA SANDI<|>SEDYNE<|>Fco. Javier Santamaría Sandi was the president of SEDyNE from March 2011 to March 2016<|>7)\n##\n(\"relationship\"<|>FCO. JAVIER SANTAMARÍA SANDI<|>CÁNCER DE TIROIDES<|>Fco. Javier Santamaría Sandi served as secretary of the Thyroid Cancer Working Group from 2012 to 2016<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: abilidad glucémica superior a alternativas como la metformina y la\n                                                                                                                                            gliburida como monoterapia inicial en la DM2.\n         COMENTARIO                                                                                                                         En general, los secretagogos de insulina tienen mayor afinidad por la subunidad SUR1 pan-\n         La enfermedad cardiovascular (ECV) ateroesclerótica, definida como enfermedad corona-                                              creática respecto de la SUR2A y SUR2B cardíacas.\n         ria, enfermedad cerebrovascular o arteriopatía periférica, es la causa principal de morbi-                                         La empagliflozina puede iniciarse hasta filtrados glomerulares estimados (FGe) de 60 ml/\n         mortalidad en personas con diabetes, y es el principal contribuyente a los costes directos e                                       min, y mantenerse hasta FGe de 45 ml/min. Los iSGLT2 deben suspenderse ante cualquier\n         indirectos de la diabetes. Para los pacientes con DM2 y ECV o enfermedad renal diabética                                           proceso intercurrente, incluida la cirugía mayor, para disminuir el riesgo de cetosis.\n         se recomienda incorporar un agente con evidencia de reducción de los eventos cardiovas-\n         culares o de la progresión de la enfermedad renal diabética, teniendo en consideración las                                         Referencias:\n         características individuales del paciente. Determinados iSGLT2 (incluida la empagliflozina)                                        •  Abdelmoneim AS, Hasenbank SE, Seubert JM, Brocks DR, Light PE, Simpson SH. Variations in tissue selectivity amongst insulin\n         y algunos agonistas de receptor de GLP1 (liraglutida, semaglutida, albiglutida) han demos-                                            secretagogues: a systematic review. Diabetes Obes Metab. 2012;14(2):130-8.\n                                                                                                                                            •  Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, et al; ADOPT Study Group. Effects of rosiglitazone, glyburide, and\n         trado ser beneficiosos desde el punto de vista de la ECV.                                                                             metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;60(5):1552-60.\n                                                                                                                                            •  Reyes-García R, Moreno-Pérez Ó, Tejera-Pérez C, Fernández-García D, Bellido-Castañeda V, de la Torre Casares ML, et al;\n         Para la prevención y el tratamiento de la ECV y la insuficiencia cardíaca, los factores de ries-                                      en representación del Grupo de trabajo de Diabetes-SEEN. Document on a comprehensive approach to type 2 diabetes mellitus.\n                                                                                                                                               Endocrinol Diabetes Nutr. 2019 Feb 28. pii: S2530-0164(19)30022-9.\n         go cardiovascular deben evaluarse sistemáticamente al menos una vez al año en todos los\n         pacientes con diabetes. Estos factores de riesgo incluyen obesidad/sobrepeso, hiperten-\n         sión, dislipidemia, consumo de tabaco, antecedentes familiares de enfermedad coronaria\n         prematura, ERC y presencia de albuminuria.\n         Referencias:\n         •  American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019.\n            Diabetes Care. 2019 Jan;42(Suppl 1):S103-23.\n         •  Reyes-García R, Moreno-Pérez Ó, Tejera-Pérez C, Fernández-García D, Bellido-Castañeda V, de la Torre Casares ML, et al;\n            en representación del Grupo de trabajo de Diabetes-SEEN.\n            Document on a comprehensive approach to type 2 diabetes mellitus. Endocrinol Diabetes Nutr. 2019 Feb 28. pii: S2530-\n            0164(19)30022-9.\n\n\n\n138                                                                                                                                                                                                                                                                           139\n---\nNO_CONTENT_HERE\n---\nMÓDULO\n\n\n\n       3                         Tiroides\n\n\n\n          AUTOR\n          Fco. Javier Santamaría Sandi\n             Especialista en Endocrinología y Nutrición. Actualmente ejerce su labor\n             como jefe de sección de Endocrinología y Nutrición en el Hospital Univer-\n             sitario Cruces desde 2007 y como profesor asociado del Departamento de\n             Medicina de la Facultad de Medicina y Odontología de la Universidad del País\n             Vasco (EPV/EHU) desde octubre 2009. Con anterioridad ha sido presidente\n             de la Sociedad de Endocrinología, Diabetes y Nutrición de Euskadi (SEDyNE)\n             desde marzo de 2011 hasta marzo de 2016 y secretario del Grupo de trabajo\n             de Cáncer de Tiroides de la Sociedad Española de Endocrinología y Nutrición\n             desde 2012 a 2016.\n             En su actividad docente e investigadora ha actuado como ponente en más\n             de 25 cursos y congresos nacionales, fundamentalmente relacionados con\n             la patología tiroidea, y es autor de 21 artículos publicados en revistas indexa-\n             das,\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}